Reduction in muscarinic M1-mediated hypercholinergic state and beneficial cognitive effects of muscarinic agonists in schizophrenia.
Pomara
Nunzio
N
D000109:Acetylcholine / Q000378:metabolism; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy*; D004298:Dopamine / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects; D006801:Humans; D018721:Muscarinic Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D019579:Neocortex / Q000187:drug effects; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D043643:Receptor, Muscarinic M1 / Q000187:drug effects*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D013830:Thiadiazoles / Q000009:adverse effects / Q000627:therapeutic use*
D018721:Muscarinic Agonists; D011725:Pyridines; D043643:Receptor, Muscarinic M1; D013830:Thiadiazoles; C075257:xanomeline; D000109:Acetylcholine; D004298:Dopamine